Format

Send to

Choose Destination
Pancreatology. 2017 Jan - Feb;17(1):1-6. doi: 10.1016/j.pan.2016.12.003. Epub 2016 Dec 12.

International consensus for the treatment of autoimmune pancreatitis.

Author information

1
Department of Gastroenterology and Hepatology, Kansai Medical University, Hirakata, Japan. Electronic address: okazaki@hirakata.kmu.ac.jp.
2
Mayo Clinic College of Medicine, Rochester, MN 55905, USA. Electronic address: chari.suresh@mayo.edu.
3
Department of Medicine, Pancreas Institute, University of Verona, Verona, Italy.
4
Department of Medicine A, University Medicine Greifswald, Germany.
5
Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
6
Center for Health, Safety, and Environmental Management, Shinshu University, Matsumoto, Japan.
7
Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
8
Service de Pancréatologie-Gastroentérologie, Pôle des Maladies de l'Appareil Digestif, Université Denis Diderot-Paris VII Hôpital Beaujon, APHP, Clichy, France.
9
Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
10
Pancreaticobiliary Medicine Unit, University College London Hospitals, London, UK.

Abstract

BACKGROUND AND AIMS:

The International Consensus Diagnostic Criteria (ICDC) for AIP has proposed two distinctive type of AIP, type 1 and type 2, and enabled us first to differentiate two types of AIP each other. By initial steroid treatment for induction of remission, remission can be successfully induced in almost all subjects with type 1 and type 2 AIP. As relapse rate in type 1 AIP is significantly higher than in type 2 AIP, there has been ongoing debate on how to treat effectively relapse of type 1 AIP.

METHODS:

By a modified Delphi approach, a panel of international experts has proposed an international consensus on the treatment of AIP after intense discussion and deliberation during an international consensus symposium of the International Association of Pancreatology (IAP) 2016.

RESULTS:

Individual statements for nine clinical questions with recommendation levels and the therapeutic strategy have been proposed.

CONCLUSION:

The recommendations are based on the available evidence, and eastern and western experts' opinions to find standard treatment of AIP worldwide. These recommendations can be tailored according to the local expertise and context in the management of individual patients.

KEYWORDS:

Autoimmune pancreatitis; Immunomodulatory; Rituximab; Steroid; Treatment

PMID:
28027896
DOI:
10.1016/j.pan.2016.12.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center